Document is current
Any future updates will be listed below
-
Authors
Chakraborty, Subhamoy
Elliott, Andrew https://orcid.org/0000-0001-8494-8031
Sen, Utsav
Coleman, Charles
Jethalia, Vrinda
Ventura, Kedwin
Fan, Chih-Wei
Sritharan, Ramja
Banerjee, Avisek
Mahendravarman, Yazhini
Vanderwalde, Ari https://orcid.org/0000-0002-6842-2563
Halmos, Balazs https://orcid.org/0000-0001-7548-8360
de Stanchina, Elisa
Taniguchi, Hirokazu
Demircioglu, Deniz https://orcid.org/0000-0001-7857-0407
Hasson, Dan
Sen, Triparna https://orcid.org/0000-0003-4673-7481
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA258784)
U.S. Department of Defense (DOD IITRA)
- License Information
-
More Information
Article History
Received: 27 November 2024
Accepted: 28 January 2026
First Online: 10 February 2026
Competing interests
: T.S. has received research grants from Jazz Pharmaceuticals. B.H. receives clinical research funding from Boehringer Ingelheim, AstraZeneca, Merck, BMS, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GSK, Beigene, Janssen, Black Diamond Therapeutics, Forward Pharma, Numab, Arrivent and receives Honoraria from AstraZeneca, Boehringer Ingelheim, Apollomics, Janssen, Takeda, Merck, BMS, Genentech, Pfizer, Eli-Lilly, Arcus, Merus, Daiichi, and Precede. He also serves on the Data Safety Monitoring Board/Advisory board for BMS, TPT, Apollomics, eFECTOR, and City of Hope. H.T. has received lecture fees from AstraZeneca, Chugai Pharmaceutical Co., Daiichi Sankyo, Taiho Pharmaceutical Co., and MSD. A.E. and A.V. are employees of Caris Life Sciences. The remaining authors declare no competing interests.
